Investlytic Investlytic
Log in Free trial
English
ETF Factsheet · Health

iShares Biotechnology ETF (IBB)

IBB ETF factsheet: fees, AUM, composition, allocation and performance, based on the positions published by the issuer.

Theme HealthIssuer ISharesClass EquityDomicile United StatesPEA no (fund domiciled outside Europe)
Symbol IBB·ISIN US4642875565·Created on 2001-02-05·Positions at 2026-11-01·Sheet of the 07/11/2026
Annual fees
0,44 %
deducted from the share value
Outstanding
11,50 $bn
in US dollars
Number of lines
246
published positions
Weight of the top 10
51,4 %
concentration
Performance 1 year
+34,8 %
price in USD
3 year performance
+78,9 %
i.e. +21,4 % per year
5 year performance
+36,1 %
i.e. +6,4 % per year
Volatilité 1 an
23,4 %
annualized standard deviation
Worst drop
-35,8 %
from a high, 5 years
Last share price
213,63 USD
+1,73 % during the session
Reading. Fees of 0,44 % per year represent 44 € collected each year for 10 000 € invested, directly in the share value. Health ETFs combine pharmaceuticals, medical equipment and biotechnologies: a defensive sector in the United States, more cyclical in its biotech part. The positions come from the issuer's publications; performance is calculated on the closing prices of the IBB listing, dividends not reinvested, in the listing currency.

10 first linesweight in the fund

Gilead Sciences, Inc.US3755581036
8,94 %
Amgen Inc.US0311621009
8,31 %
Vertex Pharmaceuticals IncorporatedUS92532F1003
7,87 %
Regeneron Pharmaceuticals, Inc.US75886F1075
6,24 %
Moderna, Inc.US60770K1079
5,49 %
Natera, Inc.US6323071042
3,78 %
argenx SEUS04016X1019
3,36 %
Biogen Inc.US09062X1037
2,52 %
Revolution Medicines, Inc.US76155X1000
2,50 %
Illumina, Inc.US4523271090
2,41 %

Sectorsaccording to the issuer

Biotechnology
87,45 %
Life Sciences Tools & Services
9,55 %
Pharmaceuticals
2,66 %
Health Care Services
0,14 %
Cash and/or Derivatives
0,10 %
Health Care Equipment
0,10 %

Countryaccording to the issuer

United States
94,28 %
Denmark
2,12 %
United Kingdom
1,54 %
Canada
0,46 %
France
0,44 %
Switzerland
0,34 %
Netherlands
0,29 %
China
0,15 %
Spain
0,13 %
Ireland
0,10 %
Australia
0,08 %
Italy
0,07 %

What you need to know

The first 10 lines make up more than half of the fund: it behaves like a basket of a few securities.

Composition: the 50 largest positions

#LineWeightValue
1Gilead Sciences, Inc.US37555810368,94 %1,03 $bn
2Amgen Inc.US03116210098,31 %953,6 M$
3Vertex Pharmaceuticals IncorporatedUS92532F10037,87 %902,8 M$
4Regeneron Pharmaceuticals, Inc.US75886F10756,24 %715,8 M$
5Moderna, Inc.US60770K10795,49 %630,5 M$
6Natera, Inc.US63230710423,78 %434,2 M$
7argenx SEUS04016X10193,36 %386,2 M$
8Biogen Inc.US09062X10372,52 %289,5 M$
9Revolution Medicines, Inc.US76155X10002,50 %287,1 M$
10Illumina, Inc.US45232710902,41 %276,6 M$
11GENMAB SPONSORED ADRGMAB2,14 %246,0 M$
12BeOne Medicines Ltd.US07725L10262,11 %242,5 M$
13United Therapeutics CorporationUS91307C10271,68 %193,2 M$
14Insmed IncorporatedUS45766930751,64 %188,5 M$
15Incyte CorporationUS45337C10271,64 %188,2 M$
16Alnylam Pharmaceuticals, Inc.US02043Q10761,49 %171,3 M$
17Roivant Sciences Ltd.BMG7627910171,31 %150,6 M$
18Charles River Laboratories International, Inc.US15986410741,15 %132,1 M$
19Exelixis, Inc.US30161Q10401,13 %129,6 M$
20Ascendis Pharma A/SDK00606157551,05 %120,8 M$
21Halozyme Therapeutics, Inc.US40637H10951,00 %114,4 M$
22Neurocrine Biosciences, Inc.US64125C10991,00 %114,3 M$
23Medpace Holdings, Inc.US58506Q10940,99 %114,1 M$
24BridgeBio Pharma, Inc.US10806X10280,89 %102,2 M$
25Bio-Techne CorporationUS09073M10450,77 %88,2 M$
26BioMarin Pharmaceutical Inc.US09061G10130,76 %87,0 M$
27Repligen CorporationUS75991610950,72 %82,6 M$
28Twist Bioscience CorporationUS90184D10000,66 %75,8 M$
29Kymera Therapeutics, Inc.US50157510440,64 %73,6 M$
30Madrigal Pharmaceuticals, Inc.US55886810570,63 %72,1 M$
31Vaxcyte, Inc.US92243G10850,61 %70,2 M$
32Protagonist Therapeutics, Inc.US74366E10290,60 %69,0 M$
33Krystal Biotech, Inc.US50114710270,58 %67,0 M$
34BioNTech SEUS09075V10260,57 %65,8 M$
35Cytokinetics, IncorporatedUS23282W60570,57 %65,4 M$
3610x Genomics, Inc.US88025U10970,55 %63,3 M$
37Arrowhead Pharmaceuticals, Inc.US04280A10070,54 %62,0 M$
38Tempus AI, Inc.US88023B10350,53 %60,5 M$
39Spyre Therapeutics, Inc.US00773J20240,52 %59,4 M$
40Praxis Precision Medicines, Inc.US74006W20700,51 %58,5 M$
41Alkermes plcIE00B56GVS150,50 %57,4 M$
42Ionis Pharmaceuticals, Inc.US46222210040,48 %55,2 M$
43Axsome Therapeutics, Inc.US05464T10430,43 %49,5 M$
44Bruker CorporationUS11679410870,43 %49,3 M$
45ABIVAX AMERICAN DEPOSITARY SHARESABVX0,43 %48,9 M$
46Rhythm Pharmaceuticals, Inc.US76243J10510,41 %47,6 M$
47GRAIL, Inc.US38474710140,41 %47,0 M$
48Kodiak Sciences Inc.US50015M10990,39 %44,8 M$
49Oruka Therapeutics, Inc.US68760410870,39 %44,3 M$
50Cogent Biosciences, Inc.US19240Q20120,33 %37,5 M$

Comparable ETFs

The overlap measures the part of the portfolio common to both funds (sum of minimum weights on shared lines): beyond 70 %, holding both provides almost no diversification.

ETFFeesOutstandingPerf. 1 yearRecovery
First Trust NYSE Arca Biotechnology Index FundFBT · First Trust0,55 %3,12 $bn+36,5 %43,9 %compare
State Street SPDR S&P Biotech ETFXBI · SPDR0,35 %10,76 $bn+39,3 %43,0 %compare
Vanguard Health Care ETFVHT · Vanguard0,09 %21,80 $bn+25,4 %19,3 %compare
Fidelity MSCI Health Care Index ETFFHLC · Fidelity0,08 %3,54 $bn+25,8 %18,8 %compare
iShares U.S. Healthcare ETFIYH · IShares0,37 %4,64 $bn+26,2 %18,1 %compare

Its holdings in other ETFsdouble exposure

The main holdings of IBB are found in many other funds: combining several ETFs often means holding the same companies several times.

  • Gilead Sciences, Inc. : 8,94 % in this fund; held by 933 ETF, 48,27 Bn$ in total
  • Amgen Inc. : 8,31 % in this fund; held by 899 ETF, 63,41 Bn$ in total
  • Vertex Pharmaceuticals Incorporated : 7,87 % in this fund; held by 779 ETF, 32,65 Bn$ in total
  • Regeneron Pharmaceuticals, Inc. : 6,24 % in this fund; held by 722 ETF, 21,94 Bn$ in total
  • Moderna, Inc. : 5,49 % in this fund; held by 485 ETF, 19,29 Bn$ in total
  • Natera, Inc. : 3,78 % in this fund; held by 381 ETF, 8,85 Bn$ in total
  • argenx SE : 3,36 % in this fund; held by 109 ETF, 1,14 Bn$ in total
  • Biogen Inc. : 2,52 % in this fund; held by 628 ETF, 8,81 Bn$ in total

Information provided for educational purposes from the positions published by the issuers and closing prices. Past performance is not indicative of future performance; fees and assets under management are those declared by the source and may contain errors. Investing involves a risk of capital loss.

Frequently Asked Questions

To understand well

What are the fees of the IBB ETF?
Reported ongoing fees are 0,44 % per year. Fees of 0,44 % per year represent 44 € collected each year for every 10 000 € invested, directly in the share value.
What are the largest positions of the iShares Biotechnology ETF?
The top ten lines weigh 51,4 % of the fund: Gilead Sciences, Inc. (8,9 %), Amgen Inc. (8,3 %), Vertex Pharmaceuticals Incorporated (7,9 %), Regeneron Pharmaceuticals, Inc. (6,2 %), Moderna, Inc. (5,5 %).
Is the IBB ETF eligible for a PEA?
No: the fund is domiciled outside the European Economic Area (ISIN US4642875565), it cannot be held in a PEA. It remains accessible in a securities account.
What is the performance of IBB over 5 years?
+36,1 % over 5 years, i.e., +6,4 % per year, in USD and dividends not reinvested (closing price at 2026-11-06).

← All ETF tools